In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

King Pharmaceuticals acquires rights to three HMR drugs

Executive Summary

King Pharmaceuticals has acquired US marketing rights to Altace (ramipril) and worldwide rights to AVC (sulfanilamide) and Silvadene (silver sulfadiazine) from Hoechst Marion Roussel for $362.5mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register